New way to halt leukemia relapse shown promising in mice
(Hiroshima University) Drugs tackling chronic myelogenous leukemia have completely transformed prognoses of patients over the last couple of decades, with most cases going into remission. But drug resistance can occur, leading to relapses. Targeting the lipids involved in regulating part of a leukemia stem cell's life span offers a potential second route to defeat the disease--and solid tumorous cancers as well. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 18, 2020 Category: Biology Source Type: news

Which Drug Therapy for CLL, Time-Limited or Continuous? Which Drug Therapy for CLL, Time-Limited or Continuous?
With several different options now available for drug treatment of chronic lymphocytic leukemia (CLL), discussions have become lengthy as the choice needs to be individualized, one expert says.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The collaboration will combine MD Anderson's clinical trials infrastructure and expertise with Astex's clinical pipeline p...
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 -- (Healthcare Sales & Marketing Network) -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),... Biopharmaceuticals, Oncology, FDA Ascentage Pharma, APG-2575, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2020 Category: Pharmaceuticals Source Type: news

INQOVI (decitabine and cedazuridine) Tablets, FDA Approved for Treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, Available at Biologics by McKesson
CARY, N.C., Aug. 24, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Taiho Oncology, Inc. as a specialty pharmacy provider for INQOVI® (decitabine and cedazuridine) tablets for the treatment of adults with intermedia... (Source: McKesson News)
Source: McKesson News - August 24, 2020 Category: Information Technology Source Type: news

Ball Score Predicts Benefit From Ibrutinib in CLL Ball Score Predicts Benefit From Ibrutinib in CLL
The BALL score was able to identify a subset of patients with chronic lymphocytic leukemia (CLL) who particularly benefited from single-agent ibrutinib therapy, according to a study of 111 patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Patient centricity: Mind the capacity gap
Pharmaceutical companies and regulators are in need of increasing amounts of input from patients throughout the entire product development lifecycle, from identifying what questions to ask in the earliest stages of research through clinical development to approval.    This usually means partnering with patient organisations and advocacy groups but pharma ’s ambitions here frequently come up against a problem. Very often, both industry and patient organisations are not set up to participate in these processes – with industry lacking systematic processes and patient advocates the required training and ...
Source: EyeForPharma - July 21, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Lymphoma Survivors at Risk for Developing Chronic Kidney Disease
MONDAY, July 20, 2020 -- Lymphoma survivors are at substantial long-term risk for chronic kidney disease (CKD) development, according to a study published online July 11 in Leukemia& Lymphoma. Sanjal H. Desai, M.D., from the Medstar Washington... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML
The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Oral Treatment for Myelodysplastic Syndrome
WEDNESDAY, July 8, 2020 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) tablets, an oral outpatient treatment option for patients with myelodysplastic syndromes and chronic myelomonocytic leukemia, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 8, 2020 Category: General Medicine Source Type: news

FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML)
Pleasanton, CA, Princeton, NJ, and Tokyo, Japan, July 7, 2020. Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration (FDA) and Health Canada have approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 8, 2020 Category: Drugs & Pharmacology Source Type: news

Blood cell mutations linked to leukemias are inevitable as we age
(RIKEN) A new study by researchers at the RIKEN Center for Integrative Medical Science in Japan reports differences in blood cell mutations between Japanese and European populations. The study found that these pre-clinical mutations were strongly associated with different types of cancers and can explain why Europeans have higher rates of chronic lymphocytic leukemia, while Japanese have higher rates of T-cell leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2020 Category: Cancer & Oncology Source Type: news

Three-Drug Combo Promising Against High-Risk CLL Three-Drug Combo Promising Against High-Risk CLL
The combination of obinutuzumab, ibrutinib, and venetoclax was associated with a high complete response rate in patients with high-risk chronic lymphocytic leukemia, a phase 2 trial finds.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 15, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Alert Source Type: news

Generic Imatinib Cuts Costs Without Affecting CML Outcomes Generic Imatinib Cuts Costs Without Affecting CML Outcomes
Clinicians and their chronic myeloid leukaemia patients looking to switch to generic imatinib will see no change in outcomes or safety, while markedly reducing healthcare costs, say UK researchers.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Rapid Cognitive Decline in a Patient With CLL Rapid Cognitive Decline in a Patient With CLL
This 68-year-old patient being treated with ofatumumab for chronic lymphocytic leukemia presented with progressive cognitive decline and neurological dysfunction. What was the cause?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 5, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

FDA Grants Orphan Drug Designation to HQP1351 for Chronic Myeloid Leukemia
The FDA granted orphan drug designation to Ascentage Pharma ’s HQP1351 for the treatment of chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

E1912 trial leads to FDA approval of ibrutinib-rituximab combo for untreated CLL
(ECOG-ACRIN Cancer Research Group) Patients aged 70 or younger with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma have a new treatment option -- a combination of the targeted agent ibrutinib with the immunologic agent rituximab. The FDA has approved the combination based on data from E1912, a phase 3 trial that showed this combination provides better leukemia control, prolongs life, and has fewer side effects compared to standard care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves Ibrutinib Plus Rituximab Combo for CLL FDA Approves Ibrutinib Plus Rituximab Combo for CLL
This combination of targeted agents showed better progression-free survival than a standard chemoimmunotherapy regimen in patients with newly diagnosed chronic lymphocytic leukemia.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s mi...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Ibrutinib Combined with Rituximab for Patients with CLL/SLL
The FDA approved ibrutinib in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 22, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Imbruvica (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
NORTH CHICAGO, Ill., April 21, 2020– AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of Imbruvica® (ibrutinib) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 21, 2020 Category: Drugs & Pharmacology Source Type: news

Finding leukemia's weakness using genome-wide CRISPR technology
(University of California - San Diego) Researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2020 Category: Cancer & Oncology Source Type: news

Prognostic Score Predicts Time to First Treatment in Leukemia
WEDNESDAY, April 15, 2020 -- An international prognostic score (IPS-E) can predict time to first treatment (TTFT) for chronic lymphocytic leukemia (CLL) patients with early, asymptomatic disease, according to a study published online April 8 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 15, 2020 Category: Pharmaceuticals Source Type: news

Treatment Tips in Chronic Lymphocytic Leukemia Treatment Tips in Chronic Lymphocytic Leukemia
A conversation with CLL specialists Drs Anthony Mato and Lindsey Roeker about the novel agents acalabrutinib, obinutuzumab, and venetoclax.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 15, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

New Score Predicts When Patients With CLL Should Start Treatment New Score Predicts When Patients With CLL Should Start Treatment
Patients with chronic lymphocytic leukemia are initially followed with active surveillance; a new prognostic score helps the decision-making process of when they should start treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Initial Ibrutinib Dose and Its Modification Do Not Affect Survival in Patients with CLL
Researchers found that in patients with chronic lymphocytic leukemia receiving commercial ibrutinib, initial dose and dose modification during therapy did not appear to impact event-free survival or overall survival. (Source: CancerNetwork)
Source: CancerNetwork - April 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Ibrutinib Interruption Tied to Worse Outcomes in CLL Ibrutinib Interruption Tied to Worse Outcomes in CLL
In a retrospective analysis, patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib had worse outcomes if the dosing was interrupted for any reason.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Investor Update - March 23, 2020 Category: Pharmaceuticals Source Type: news

Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Media News - March 23, 2020 Category: Pharmaceuticals Source Type: news

Researchers in Singapore find common therapeutic vulnerability for a genetically diverse and deadly
(Duke-NUS Medical School) Scientists and clinicians from Duke-NUS Medical School, the Agency for Science, Technology and Research's (A*STAR's) Genome Institute of Singapore (GIS), and the Singapore General Hospital (SGH), have devised a novel drug combination that could treat a particularly deadly form of leukaemia, known as blast crisis (BC) chronic myeloid leukaemia (CML). The team has also developed strategies that may identify patients with early stage or chronic phase (CP) CML who are at increased risk of developing BC, and potentially preventing disease progression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2020 Category: Cancer & Oncology Source Type: news

AbbVie Receives European Commission Approval of VENCLYXTO(R) Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously untreated chronic lymphocytic leukemia (CLL) Approval is based on data from the Pha... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 12, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
Basel, 12 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).“Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development...
Source: Roche Media News - March 12, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
Basel, 12 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).“Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development...
Source: Roche Investor Update - March 12, 2020 Category: Pharmaceuticals Source Type: news

Jennifer A. Woyach, MD, on Frontline Treatments for Patients with CLL
The associate professor of hematology spoke with CancerNetwork ®about frontline treatments available for patients with chronic lymphocytic leukemia and the toxicities present for these treatments. (Source: CancerNetwork)
Source: CancerNetwork - March 11, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

What Causes Neutropenia?
Discussion Neuropenia is defined as a neutrophil count
Source: PediatricEducation.org - March 2, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Invasive Aspergillosis in the Setting of Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 29, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
(University of Texas M. D. Anderson Cancer Center) According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2020 Category: Cancer & Oncology Source Type: news

Phase I Trial Aims to Evaluate Cobomarsen in Certain Hematologic Malignancies
The phase I trial is evaluating cobomarsen in cancers where the disease process appears to be correlated with an increase in miR-155 levels, including adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 4, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA clears investigational new drug application for Calibr's 'switchable' CAR-T therapy
(Scripps Research Institute) Calibr, the drug discovery and development division of Scripps Research, today announced that the US Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's 'switchable' CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 3, 2020 Category: International Medicine & Public Health Source Type: news

AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with a fixed duration for patients with previously untreated chronic lymphocytic leukemia (CLL) Represents thir... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 31, 2020 Category: Pharmaceuticals Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product ...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news

Single-cell sequencing of CLL therapy: Shared genetic program, patient-specific execution
(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Researchers at the CeMM Research Center for Molecular Medicine and partners in Budapest have studied the response to targeted leukemia therapy in unprecedented detail, using single-cell sequencing and epigenetic analysis. The paper published in Nature Communications uncovers a precise molecular program in patients with chronic lymphocytic leukemia (CLL) who start treatment with ibrutinib. While this program was shared by all patients, the speed of its execution differed widely. These results will help develop personalized strategies for manag...
Source: EurekAlert! - Cancer - January 29, 2020 Category: Cancer & Oncology Source Type: news

Idelalisib May Induce More Favorable Outcomes in Clinical Trial Participants, Versus Medicare Beneficiaries
Medicare beneficiaries saw unfavorable results when compared to clinical trial participants being treated with idelalisib for their follicular lymphoma or chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - January 17, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Jennifer A. Woyach, MD, on the Alliance A041702 Trial in Chronic Lymphocytic Leukemia
The Ohio State University Comprehensive Cancer Center expert discussed the ongoing Alliance A041702 trial at the ASH Annual Meeting and Exposition. (Source: CancerNetwork)
Source: CancerNetwork - January 2, 2020 Category: Cancer & Oncology Authors: Jennifer A. Woyach, MD Source Type: news

CLL Highlights From ASH 2019 CLL Highlights From ASH 2019
Dr William Wierda of MD Anderson Cancer Center reviews key studies on chronic lymphocytic leukemia therapies presented at the 2019 American Society of Hematology (ASH) meeting in Orlando, Florida.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

Revolutionary two-pronged attack that's beating 'incurable' blood cancer 
Professor Lelia Duley, 61, from Southwell in Nottinghamshire, is one of the patients involved in a drug combination trial to combat chronic lymphocytic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - December 28, 2019 Category: Consumer Health News Source Type: news